<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514278</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/33</org_study_id>
    <nct_id>NCT02514278</nct_id>
  </id_info>
  <brief_title>Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy</brief_title>
  <acronym>GRECCAR12</acronym>
  <official_title>Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A
      new concept suggests organ preservation as an alternative to rectal excision in good
      responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase
      quality of life. The rational is the fact that 15% of patients have sterilized tumours after
      radiochemotherapy for T3T4 rectal cancer. The French GRECCAR 2 trial is the first phase III
      trial investigating this strategy: patients with T2T3 low rectal carcinomas (size ≤4 cm)
      received 50 Gy with capecitabine and good clinical responders (≤2 cm) were randomized between
      local and rectal excision. The main findings were: the rate of complete pathologic response
      was higher after radiochemotherapy for small T2T3 than for T3T4 tumours (40% vs 15% ypT0) and
      good pathologic responders (ypT0-1) were associated with zero positive mesorectal nodes.

      The objective of the new trial is to increase the proportion of patients treated with organ
      preservation by optimizing tumour response. As compared to Folfiri, tritherapy Folfirinox has
      been shown to enhance the response rate. In patients with colorectal metastases, response
      rate and R0 resection were twice higher, resulting in improved survival. Folfirinox also
      increases response and chance of R0 resection rates in initially unresectable colorectal
      metastases, compared to standard or intensified bi-chemotherapy regimens. Adding two months
      of neoadjuvant chemotherapy (Folfirinox) before radiochemotherapy, the investigators expect
      to increase chance of organ preservation rate, as compared to radiochemotherapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of organ preservation and absence of stoma</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Number of patients with organ preservation and absence of stoma at 1 year after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment</time_frame>
    <description>Number of patients receiving full neoadjuvent treatment and the allocated surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until 1 year after surgery</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical complete response</measure>
    <time_frame>At 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of grade 1 : no tumor at digital examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radiological response</measure>
    <time_frame>At 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of tumor ≤ 2 cm with TRG1-3 at MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete pathologic response</measure>
    <time_frame>At surgery, expected average 10 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of ypT0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between radiological and clinical response</measure>
    <time_frame>Between 8 to 10 weeks after neoadjuvant treatment</time_frame>
    <description>To analyse the correlation between radiological response ( tumor ≤ 2 cm with TRG1-3 at MRI) and clinical response (grade 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between radiological and pathologic response</measure>
    <time_frame>Between 8 to 10 weeks after neoadjuvant treatment</time_frame>
    <description>To analyse the correlation between radiological response ( tumor ≤ 2 cm with TRG1-3 at MRI) and pathological response (ypT0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curative surgery</measure>
    <time_frame>At surgery, expected average 10 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of R0 resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>From surgery until 1 year of follow-up</time_frame>
    <description>To analyse the cumulative Clavien-Dindo at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From randomization until 1 year after surgery</time_frame>
    <description>To examine score of questionnaires : QLQ CR-30, QLQ CR-29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of local recurrence at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of disease-free survival at 3 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy Folfirinox, 4 cycles:
oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU: 2400 mg/m2
Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy Folfirinox, 4 cycles</intervention_name>
    <description>oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU: 2400 mg/m2</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>50 Gy, 2 Gy/session; 25 fractions</intervention_name>
    <description>Radiochemotherapy 5 weeks</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local excision in good responders</intervention_name>
    <description>If local excision:
Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)
Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal excision in bad responders</intervention_name>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1600 mg/m2 daily 5 days/7</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rectal adenocarcinoma

          -  cT2T3

          -  cN0-1 (≤ 3 lymph nodes, size ≤8mm)

          -  Tumour size ≤4 cm

          -  Location ≤10 cm from the anal verge

          -  No distant metastasis

          -  Patient ≥18 years

          -  ECOG ≤2

          -  Effective contraception during the study

          -  Patient and doctor have signed informed consent

        Exclusion Criteria:

          -  T1 or T4

          -  Tumour size &gt;4cm

          -  N2 (&gt;3 lymph nodes or size &gt;8mm)

          -  Tumour &gt; 10 cm from the anal verge

          -  Distant metastasis

          -  Chronic intestinal inflammation and/or bowel obstruction

          -  Contra indication for chemotherapy and/or radiotherapy

          -  Previous pelvic radiotherapy or chemotherapy

          -  Severe renal, hepatic insufficiency (serum creatinine&lt;30ml/min)

          -  Peripheral neuropathy &gt; grade 1

          -  Dihydropyrimidine dehydrogenase deficiency

          -  Concomitant treatment with millepertuis, yellow fever vaccine, phenytoin or sorivudine
             (or chemically equivalent)

          -  Pregnant or breast-feeding woman.

          -  Persons deprived of liberty or under guardianship

          -  Impossibility for compliance to follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric RULLIER, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric RULLIER, Prof.</last_name>
    <phone>(0)5 56 79 58 10</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.rullier@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc REGIMBEAU</last_name>
      <email>regimbeau.jean-marc@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges MANTION</last_name>
      <email>georges.mantion@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-André - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric RULLIER</last_name>
      <email>eric.rullier@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge EVRARD</last_name>
      <email>S.Evrard@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Estaing - CHRU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis PEZET</last_name>
      <email>dpezet@chu.clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Beaujon - APHP</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves PANIS</last_name>
      <email>yves.panis@bjn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Georges François Leclerc - Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David ORRY</last_name>
      <email>dorry@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Albert Michallon - CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc FAUCHERON</last_name>
      <email>JLFaucheron@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Oscar Lambret - Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehrad JAFARI</last_name>
      <email>m-jafari@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe MARIETTE</last_name>
      <email>christophe.mariette@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Léon Bérard - Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel RIVOIRE</last_name>
      <email>rivoire@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Lyon Sud - CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddy COTTE</last_name>
      <email>eddy.cotte@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU de la Timone - Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor SIELEZNEFF</last_name>
      <email>Bernard.Sastre@mail.ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut Paoli Calmette - Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard LELONG</last_name>
      <email>lelongb@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Saint-Eloi - Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel FABRE</last_name>
      <email>jm-fabre@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROUANET</last_name>
      <email>phillipe.rouanet@montpellier.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive,Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric MARCHAL</last_name>
      <email>f.marchal@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôtel Dieu - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume MEURETTE</last_name>
      <email>guillaume.meurette@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Carémeau - Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel PRUDHOMME</last_name>
      <email>michel.prudhomme@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane BENOIST</last_name>
      <email>stephane.benoist@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital les Diaconnesses</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri MOSNIER</last_name>
      <email>hmosnier@hopital-dcss.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Pitié Salpetrière - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Medhi KAROUI</last_name>
      <email>medhi.karoui@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-Antoine - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel TIRET</last_name>
      <email>emmanuel.tiret@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-Louis - APHP Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mircea CHIRICA</last_name>
      <email>mircea.chirica@sls.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Pontchaillou - CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard MEUNIER</last_name>
      <email>bernard.meunier@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Charles Nicolle - CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques TUECH</last_name>
      <email>jean-jacques.tuech@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Purpan - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume PORTIER</last_name>
      <email>portier.g@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie digestive, CHRU de Nancy -Hôpital de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeline GERMAIN</last_name>
      <email>a.germain@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de chirurgie digestive, Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léonor BENHAIM</last_name>
      <email>leonor.benhaim@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Organ preservation</keyword>
  <keyword>Local excision</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Folfirinox</keyword>
  <keyword>Tumour response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

